Shopping Cart
- Remove All
- Your shopping cart is currently empty
EZH2-IN-7, a potent inhibitor of EZH2, addresses overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) that cause an abnormal increase in H3K27me3, contributing to the proliferation of various tumors, including breast cancer, prostate cancer, and leukemia. It shows promise for cancer research applications.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,670 | 6-8 weeks | |
50 mg | $2,180 | 6-8 weeks | |
100 mg | $2,800 | 6-8 weeks |
Description | EZH2-IN-7, a potent inhibitor of EZH2, addresses overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) that cause an abnormal increase in H3K27me3, contributing to the proliferation of various tumors, including breast cancer, prostate cancer, and leukemia. It shows promise for cancer research applications. |
Molecular Weight | 563.75 |
Formula | C31H37D2N5O3S |
Cas No. | 2659225-28-0 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.